Quantcast

Industry news that matters to you.  Learn more

Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, recently announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Independent Study: Health Diagnostic Laboratory, Inc. Services Lead to Cost Savings of 23% and Significantly Improved Health Outcomes After Two Years

Advanced cardiometabolic testing paired with follow-up health management from Health Diagnostic Laboratory, Inc. has resulted in a 23 percent decrease in a patient’s overall healthcare costs and an improved lipid profile in just two years, according to a new independent study published recently in Population Health Management.

Health Diagnostic Laboratory, Inc.’s New Diabetes Prevention & Management Panel Incorporates Discovery from Metabolon Researchers

Health Diagnostic Laboratory, Inc., a CLIA-certified laboratory specializing in advanced cardiovascular and metabolic disease testing and health management, has launched a new blood test for stratifying prediabetic patients based on the Quantose™ insulin resistance markers discovered by Metabolon, Inc.

Insulin resistance is a primary risk factor for type 2 diabetes and cardiovascular complications, and the Quantose biomarkers have been incorporated into HDL, Inc.’s newly launched Diabetes Prevention & Management Panel, or DPMP. Following a soft-launch period of limited release, development, and test marketing, HDL, Inc. has incorporated the Quantose™ metabolites seamlessly into DPMP, a 21-test panel available to physicians nationwide beginning this month. Terms of the deal were not disclosed.

“The ability to more accurately identify patients likely to progress to full-blown type 2 diabetes is a powerful tool to help manage the onset of a leading cause of heart disease,” said Tonya Mallory, HDL, Inc.’s President, CEO and Co-founder. “The Quantose markers help complete Health Diagnostic Laboratory’s DPMP and provide physicians with a more accurate, deeper look at the root causes of prediabetes and diabetes.”

Diabetes affects 25.8 million people in the U.S., or 8.3 percent of the population, according to the American Diabetes Association. Nearly one in three U.S. adults – almost 80 million people – meet the criteria for prediabetes.

The Quantose™ biomarkers are novel metabolites detected in blood that reflect insulin resistance and detect progression to prediabetes and diabetes earlier than traditional glycemic measures such as HbA1c. By considering insulin resistance, metabolites provide clinicians with a useful tool that goes beyond traditional measures to stratify patients based on their risk for developing diabetes. The Quantose™markers are particularly useful in identifying prediabetic patients at the greatest risk of disease progression where drug or other interventional therapy may be appropriate. Such a clinical value is well-aligned with American Diabetes Association guidelines, which recommend physicians consider pharmaceutical intervention in high-risk prediabetic patients.

”We are delighted to have an ideal partner in Health Diagnostic Laboratory to bring American clinicians a new tool for identifying and managing patients at risk for developing diabetes,” said John Ryals, CEO of Metabolon. “Our expertise in biochemical profiling is reflected in the discovery of the Quantose markers and represents the culmination of many years of research by our scientists. Importantly, if physicians are able to detect high-risk prediabetic patients earlier, it may allow them to initiate therapeutic interventions capable of preventing diabetes and related complications. The launch of Health Diagnostic Laboratory’s DPMP using the Quantose markers also represents a significant milestone in Metabolon’s evolution from providing biomarker analysis services to discovering cutting-edge metabolomic-based diagnostic markers.”

Source: PR Newswire

Mayo Medical Laboratories and Atherotech Diagnostics Lab to Offer Critical Diagnostics’ ST2 Test

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that two major reference laboratories — Mayo Medical Laboratories and Atherotech Diagnostics Lab — will offer the company’s Presage ST2 test. The Presage ST2 Assay was recently cleared by the U.S. Food and Drug Administration for use in assessing the prognosis of patients diagnosed with chronic heart failure.